0
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function due to damage to the myelin sheath that insulates nerve fibers. It is believed to be an autoimmune condition, where the body's immune system mistakenly attacks the peripheral nerves. Symptoms often include muscle weakness, numbness, and fatigue, and they can vary in severity. Treatment typically involves immunotherapy, such as corticosteroids or intravenous immunoglobulin (IVIG), to reduce inflammation and improve nerve function.
What else can I help you with?
Does anyone use norco or vicodin 10-325 for chronic inflammatory demyelinating polyneuropathy?
i have ms and cidp. i am looking for other people who use hydrocodone or norco or vicodin
How does igg help cidp?
IgG therapy is thought to help CIDP (chronic inflammatory demyelinating polyneuropathy) by reducing inflammation in the peripheral nerves and modifying the immune response. It can help to stabilize the condition and improve nerve function in some patients with CIDP.
What is the ICD-9 code for Guillain-Barre Syndrome?
The ICD-9 code for Guillain-Barré Syndrome is 357.0. This code falls under the category of inflammatory and demyelinating diseases of the nervous system. It specifically refers to acute inflammatory demyelinating polyneuropathy, which is the most common form of Guillain-Barré Syndrome.
What are the demographics of chronic inflammatory demyelinating polyneruopathy?
Chronic inflammatory demyelinating polyneuropathy (CIDP) can affect individuals of any age, but it's more commonly diagnosed in adults, with a peak incidence between 40-60 years old. Both men and women are affected, although CIDP is slightly more prevalent in men. There is no specific racial or ethnic predilection for CIDP.
Are their any support groups for people with Chronic Inflammatory Demylinating Polyneuropathy in the Los Angeles area?
not in l.a. but one in palm springs
Is cidp an autoimune diseae?
Yes, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is classified as an autoimmune disease. In CIDP, the immune system mistakenly attacks the peripheral nerves, leading to inflammation and damage to the myelin sheath that insulates these nerves. This results in symptoms such as weakness, numbness, and impaired motor function. Treatment often involves therapies aimed at modulating the immune response.
Is sensory demyelinating polyneuropathy an afferent pathway problem?
Yes, sensory demyelinating polyneuropathy primarily affects the sensory nerve fibers by damaging the myelin sheath that surrounds them. This results in impaired transmission of sensory signals from the peripheral nerves to the central nervous system, leading to symptoms such as numbness, tingling, and reduced sensation.
Is Refrigerator Perry still living?
Yes. Perry was hospitalized in April, 2009 for Chronic Inflammatory Demyelinating Polyneuropathy, a disease that affects the nervous system and is a result of being afflicted with Guillain-Barre Syndrome, a disease where the immune system attacks the nerves causing weakness and numbness in the arms and legs. Perry was hospitalized for about 5 weeks and left the hospital to receive rehabilation at an undisclosed location.
Is IVIG used to treat the repair of the myelin on nerves?
Intravenous immunoglobulin (IVIG) is not primarily used to repair myelin on nerves, but it can play a role in treating certain autoimmune conditions that affect myelin, such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). IVIG works by modulating the immune system, helping to reduce inflammation and potentially aiding in the recovery of nerve function. While it may support the healing process, it does not directly promote myelin repair.
What is chronic inflammatory?
Prolonged inflammation, healing of the tissue from the inflammatory process
How did guillain-barre syndrome get its name?
Guillain-Barré syndrome is named after the French neurologists Georges Guillain and Jean Alexandre Barré, who, along with their colleague André Strohl, first described the condition in a medical paper published in 1916. They identified the syndrome as an acute inflammatory demyelinating polyneuropathy characterized by rapid-onset muscle weakness and paralysis. The naming honors their contributions to understanding this neurological disorder.
Chronic inflammatory myopathy of uncertain etiology?
polymyositis
